FDA approval clears first oral orexin therapy for narcolepsy type 1

The FDA has approved Takeda’s first-in-class oral orexin receptor 2 agonist Orzeyful (oveporexton) for adults with narcolepsy type 1. Takeda said the therapy is designed to address an underlying cause of the disorder, with approval announced Aug. 5 after earlier clearance from China’s NMPA on July 22.